Assessing the Effects of Non-steroidal Anti-inflammatory Drugs on Antihypertensive Drug Therapy Using Post-Marketing Surveillance Database

Background Antihypertensive and non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat many common diseases. However, it has been suspected that interactions between these drugs exist. Here, we assessed the interactions between non-selective NSAIDs and several classes of antihypertensive drugs. Methods The study design was a cohort study using “The Antihypertensive Drug Database,” which is a collection of data accumulated from Drug Use Investigations. Subjects newly starting antihypertensive drug therapy were identified in the database. We compared the “User” group, who were co-administered NSAIDs, with the “Non-user” group, who were not. The outcome measure was the change in systolic blood pressure from the baseline after 2 months of treatment. We estimated the non-adjusted and adjusted differences in the change in systolic blood pressure between the “User” and “Non-user” groups. Results Data were collected for a total of 1,204 subjects, of whom 364 were prescribed beta blockers, 60 were prescribed diuretics, 628 were prescribed angiotensin-converting enzyme inhibitors, and 152 were prescribed calcium channel blockers. The adjusted difference in the change in systolic blood pressure between the User (n = 301) and Non-user (n = 903) groups was 2.88 mmHg (95% confidence interval: 0.89, 4.87); thus, systolic blood pressure in the Non-User group decreased further from the baseline than that in the User group. In subjects administered beta blockers, diuretics, angiotensin-converting enzyme inhibitors, and calcium channel blockers, the corresponding differences were 0.37 mmHg (-3.24, 3.98), 6.11 mmHg (-3.16, 15.37), 3.85 mmHg (1.16, 6.66), and 3.50 mmHg (-2.03, 9.02). Conclusion The effectiveness of antihypertensive drugs was attenuated by the co-administration of NSAIDs. The differences in the effects of NSAIDs varied with different classes of antihypertensive drugs.

[1]  Subcommittee Guidelines Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). , 2006, Hypertension research : official journal of the Japanese Society of Hypertension.

[2]  H. Black,et al.  Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. , 2000, Hypertension.

[3]  J. Schlesselman,et al.  Sample size requirements in cohort and case-control studies of disease. , 1974, American journal of epidemiology.

[4]  M Marmot,et al.  INTERSALT Study Findings Public Health and Medical Care Implications , 1989, Hypertension.

[5]  B. Kuehn FDA panel: keep COX-2 drugs on market: black box for COX-2 labels, caution urged for all NSAIDs. , 2005, JAMA.

[6]  Lippincott Williams Wilkins,et al.  1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. , 1993, Hypertension.

[7]  Arterial hypertension. Report of a WHO expert committee. , 1978, World Health Organization technical report series.

[8]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[9]  D. Young,et al.  Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine. , 1995, American journal of hypertension.

[10]  M. Leider Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[11]  Trefor Owen Morgan,et al.  Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. , 2000, American journal of hypertension.

[12]  W. White Hypertension associated with therapies to treat arthritis and pain. , 2004, Hypertension.

[13]  J. Gerber,et al.  Propranolol Increases Prostacyclin Synthesis in Patients with Essential Hypertension , 1988, Hypertension.

[14]  J. Robins,et al.  Estimating exposure effects by modelling the expectation of exposure conditional on confounders. , 1992, Biometrics.

[15]  Roger L. Black,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .

[16]  R. Day,et al.  Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis , 1994, Annals of Internal Medicine.

[17]  H. Friza Report of a WHO Expert Committee. (WHO Technical Report Series No. 807), VI. World Health Organization, Geneva (1991), 65 pages, Soft cover SFr. 11 , 1993 .

[18]  T. Saruta [The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[19]  A. Hida,et al.  Basic Characteristics of Chronic Hypotension Cases: A Longitudinal Follow-Up Study from 1958 through 1999 , 2006, Hypertension Research.

[20]  J. Ménard,et al.  Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. Subcommittee of WHO/ISH Mild Hypertension Liaison committee. , 1993, BMJ.

[21]  G. Ruoff The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. , 1998, Clinical therapeutics.

[22]  F. Arellano The withdrawal of rofecoxib , 2005, Pharmacoepidemiology and drug safety.